|
1
|
Vucinovic A, Bukic J, Rusic D, Leskur D, Seselja Perisin A, Radic M, Grahovac M, Modun D. Evaluation of Reporting Quality of Glaucoma Randomized Controlled Trial Abstracts: Current Status and Future Perspectives. Life (Basel) 2024; 14:117. [PMID: 38255732 PMCID: PMC10820560 DOI: 10.3390/life14010117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Revised: 01/09/2024] [Accepted: 01/10/2024] [Indexed: 01/24/2024] Open
Abstract
The aim of this study was to explore adherence to the Consolidated Standards of Reporting Trials (CONSORT) reporting standards in abstracts of randomized controlled trials on glaucoma. A cross-sectional observational study was conducted on the aforementioned abstracts, indexed in MEDLINE/PubMed between the years 2017 and 2021. In total, 302 abstracts met the inclusion criteria and were further analyzed. The median score of CONSORT-A items was 8 (interquartile range, 7-10) out of 17 (47.0%). Most analyzed studies were conducted in a single center (80.5%) and the abstracts were predominantly structured (95.0%). Only 20.5% of the abstracts adequately described the trial design, while randomization and funding were described by 6.0% of the abstracts. Higher overall scores were associated with structured abstracts, a multicenter setting, statistically significant results, funding by industry, a higher number of participants, and having been published in journals with impact factors above four (p < 0.001, respectively). The results of this study indicate a suboptimal adherence to CONSORT-A reporting standards, especially in particular items such as randomization and funding. Since these factors could contribute to the overall quality of the trials and further translation of trial results into clinical practice, an improvement in glaucoma research reporting transparency is needed.
Collapse
Affiliation(s)
- Ana Vucinovic
- Department of Ophthalmology, University Hospital Centre Split, Spinciceva 1, 21000 Split, Croatia;
| | - Josipa Bukic
- Department of Pharmacy, University of Split School of Medicine, Soltanska 2, 21000 Split, Croatia; (D.R.); (D.L.); (A.S.P.); (M.G.); (D.M.)
| | - Doris Rusic
- Department of Pharmacy, University of Split School of Medicine, Soltanska 2, 21000 Split, Croatia; (D.R.); (D.L.); (A.S.P.); (M.G.); (D.M.)
| | - Dario Leskur
- Department of Pharmacy, University of Split School of Medicine, Soltanska 2, 21000 Split, Croatia; (D.R.); (D.L.); (A.S.P.); (M.G.); (D.M.)
| | - Ana Seselja Perisin
- Department of Pharmacy, University of Split School of Medicine, Soltanska 2, 21000 Split, Croatia; (D.R.); (D.L.); (A.S.P.); (M.G.); (D.M.)
| | - Marijana Radic
- Department of Neurology, General Hospital Pula, Santoriova 24a, 52100 Pula, Croatia;
| | - Marko Grahovac
- Department of Pharmacy, University of Split School of Medicine, Soltanska 2, 21000 Split, Croatia; (D.R.); (D.L.); (A.S.P.); (M.G.); (D.M.)
| | - Darko Modun
- Department of Pharmacy, University of Split School of Medicine, Soltanska 2, 21000 Split, Croatia; (D.R.); (D.L.); (A.S.P.); (M.G.); (D.M.)
| |
Collapse
|